Drug Profile


Alternative Names: EPO-hFC; EPO-hybrid Fc; EPO-hyFc; GC-1113; GX-E2; Long-acting EPO; Recombinant erythropoietin long-acting - Genexine/Green Cross

Latest Information Update: 29 Feb 2016

Price : $50

At a glance

  • Originator Genexine
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 25 Feb 2016 Phase-II development is ongoing in South Korea
  • 16 Feb 2016 GX E2 licensed to Shanghai ChemoWanbang Biopharma in China
  • 01 Jan 2015 Genexine completes a phase I trial in Anaemia (In volunteers) in South Korea (NCT02291991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top